Long-Term Outcomes of Heart Transplantation Using Hepatitis C–Positive Donors
Transplantation Proceedings · 2026
DOI: 10.1016/j.transproceed.2026.07.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von You-Min Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, Cheng Hsin General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Heart Transplantation, Hepatitis C, Tissue Donors. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The global shortage of donor organs has prompted the utilization of extended criteria donors, including those infected with hepatitis C virus (HCV). While direct-acting antivirals (DAAs) have made this strategy feasible, data regarding long-term outcomes in the Asian population remain limited. We aimed to evaluate the long-term survival outcomes of heart transplantation (HT) using HCV-positive donors in a single-center Asian cohort. METHODS: This retrospective study analyzed 451 adult HT recipients at a single center in Taiwan between July 1, 1988, and June 30, 2024. Patients were stratified into HCV-positive donor (n = 20) and HCV-negative donor (n = 431) groups. Propensity score overlap weighting (OW) was employed to balance baseline characteristics. The primary endpoint was long-term all-cause mortality. RESULTS: The median follow-up duration was 10.5 years. All recipients of HCV-positive hearts who developed viremia achieved a sustained virologic response (SVR12) with DAA therapy, resulting in a final cure rate of 100%. Kaplan-Meier analysis revealed no significant difference in long-term survival between the 2 groups (log-rank P = .136). In the overlap-weighted Cox proportional hazards model, donor HCV status was not an independent predictor of 10-year mortality (adjusted hazard ratio [HR] 1.88; 95% confidence interval [CI] 0.50-7.05; P = .350). CONCLUSIONS: HT using HCV-positive donors is a viable strategy in the Asian population, yielding long-term survival comparable to that of HCV-negative donors. With the availability of effective DAA therapy, this approach can be successfully implemented to expand the donor pool without compromising recipient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy, Cheng Hsin General Hospital, Taipei, Taiwan.
- Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan.
- Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan.
- Office of the Superintendent, Cheng Hsin General Hospital, Taipei, Taiwan. Electronic address: chgh2014oth@gmail.com.
Zitieren
APA
Lu, Y. M., Chen, P. S., Lee, Y. C., Ling, S. M., Chang, C. Y., Chang, C. Y., & Wei, J. (2026). Long-Term Outcomes of Heart Transplantation Using Hepatitis C–Positive Donors. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2026.07.021
Vancouver
Lu YM, Chen PS, Lee YC, Ling SM, Chang CY, Chang CY, et al. Long-Term Outcomes of Heart Transplantation Using Hepatitis C–Positive Donors. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2026.07.021
BibTeX
@article{Lu2026,
author = {Lu, You-Min and Chen, Po-Sung and Lee, Yi-Chan and Ling, Sheng-Ming and Chang, Chih-Ying and Chang, Chung-Yi and Wei, Jeng},
title = {Long-Term Outcomes of Heart Transplantation Using Hepatitis C–Positive Donors},
journal = {Transplantation Proceedings},
year = {2026},
doi = {10.1016/j.transproceed.2026.07.021}
}
EUVIMED